Menkes Disease is a genetic disorder affecting the metabolism of copper. Patient with this disease are both physically and mentally retarded. Menkes disease is usually first detected in the first 2-3 months of life. Infant males born with the disease fail to thrive, experience hypothermia, have delayed development, and experience seizures. These infants also have characteristic physical features such as changes of their hair and face. Females may also have changes in hair and skin color, but rarely have significant medical problems.

Appropriate treatment of Menkes Disease requires that the disease be diagnosed early and treatment started before irreversible brain damage occurs. The aim of treatment is to bypass the normal route of absorption of copper through the gastrointestinal tract. Copper must then be delivered to brain cells and be available for use by enzymes.

Copper histidine is a copper replacement that can be injected directly into the body to avoid absorption through the gastrointestinal tract. However, studies have shown the genetic abnormalities causing Menkes disease cannot simply be corrected by copper replacement injections.

The genetic abnormality causing Menkes disease can vary in its severity. Patients with a genetic abnormality that may still permit some production of the enzymes required to process copper may receive benefit from early treatment with copper replacement. However, patients with severe abnormalities of the genes responsible for copper metabolism may receive no benefit from copper replacement.

The purpose of this study is to continue to evaluate the effects of early copper histidine in Menkes disease patients and to correlate specific molecular defects with responses to treatment.

Condition	Treatment or Intervention	Phase
Kinky Hair Syndrome	Drug: Copper Histidine	Phase II

Menkes disease is an X-linked recessive neurodegenerative disorder caused by defects in a gene that encodes an evolutionary conserved copper-transporting ATPase (ATP7A). Several issues must be addressed in configuring therapeutic strategies for this disorder: (a) affected infants must be identified and treatment commenced very early in life before irreparable neurodegeneration occurs. (b) the block in intestinal absorption of copper must be bypassed, (c) circulating copper must be delivered to the brain, and (d) copper must be available to enzymes within cells that require it as a cofactor. Very early, pre-symptomatic therapy with copper injections has been associated with improved neurological outcomes in some, though not all, affected Menkes disease infants. The purpose of this study is to further evaluate the potential efficacy of this treatment and, in concert with molecular and cellular bench studies, to discern the relationship between specific mutations at the Menkes disease locus and treatment responsiveness, as measured by the quality of neurodevelopmental outcomes.

Genders Eligible for Study:  Both

Criteria

INCLUSION CRITERIA:
Newborn infants in whom Menkes disease is confirmed on biochemical or molecular grounds and in whom no neurological symptoms are present are eligible for enrollment in this study.

Maryland
      National Institute of Neurological Disorders and Stroke (NINDS), 9000 Rockville Pike,  Bethesda,  Maryland,  20892,  United States; Recruiting

Study ID Numbers:  900149; 90-N-0149
Record last reviewed:  June 25, 2003
Last Updated:  June 25, 2003
Record first received:  November 3, 1999
ClinicalTrials.gov Identifier:  NCT00001262
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2004-11-08